Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been in high demand worldwide since the outbreak of the COVID-19 pandemic. Croatia is no exception, as the country has seen an increase in the usage of antiviral drugs in recent times.
Customer preferences: Croatian customers have shown a preference for antiviral drugs that are effective against a wide range of viruses. They are also willing to pay a premium for drugs that have minimal side effects and can be easily administered.
Trends in the market: The antiviral drug market in Croatia has been growing steadily due to the increase in the prevalence of viral diseases. The COVID-19 pandemic has also led to a surge in demand for antiviral drugs, especially those that have been proven to be effective against the virus. In addition, the market has seen an increase in the number of local manufacturers of antiviral drugs, which has led to increased competition and lower prices for consumers.
Local special circumstances: Croatia has a well-developed healthcare system that provides universal coverage to its citizens. The government has also taken steps to ensure that antiviral drugs are readily available to those who need them. In addition, the country has a high level of health literacy, which has led to increased awareness about the benefits of antiviral drugs.
Underlying macroeconomic factors: The Croatian economy has been growing steadily in recent years, which has led to an increase in disposable income for consumers. This has contributed to the growth of the antiviral drug market, as consumers are more willing to spend money on healthcare products. In addition, the government has been investing in the healthcare sector, which has led to the development of new drugs and treatments. In conclusion, the antiviral drug market in Croatia has been growing steadily due to a combination of factors, including the increase in the prevalence of viral diseases, the COVID-19 pandemic, and the growth of the Croatian economy. The market is expected to continue to grow in the coming years, as consumers become more aware of the benefits of antiviral drugs and the government continues to invest in the healthcare sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
